BRAF and melanoma: The unique role of HGF/MET signaling in conferring resistance to MAPK pathway inhibitors in BRAF and NRAS mutant melanoma suggests that combination therapy with small-molecule MET inhibitors may provide additional benefit beyond BRAF and MEK inhibitors alone.